EC
HUMA icon

EntryPoint Capital’s Humacyte HUMA Stock Holding History

EntryPoint Capital’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-77,996
Closed -$424K – 834
2024
Q3 		$424K Buy
77,996
+72,816
+1,406% +$480K 0.24% 106
2024
Q2 		$24.9K Sell
5,180
-26,948
-84% -$140K 0.04% 681
2024
Q1 		$99.9K Sell
32,128
-779
-2% -$2.62K 0.09% 423
2023
Q4 		$93.5K Buy
+32,907
New +$84.5K 0.09% 414

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

EntryPoint Capital's HUMA Position: Q4 2024 in Review

EntryPoint Capital sold out of Humacyte (HUMA) in Q4 2024, closing a stake of 77,996 shares — an estimated $424K sold.

EntryPoint Capital first reported a position in HUMA in Q4 2023 and held it in 4 quarters. The position peaked at $424K in Q3 2024. 162 funds tracked by Wall St. Rank hold HUMA as of Q4 2024.

  • EntryPoint Capital reported no remaining Humacyte position as of Q4 2024 after selling out during the quarter.
  • EntryPoint Capital sold 77,996 Humacyte shares in Q4 2024, an estimated $424K.
  • EntryPoint Capital first reported a position in Humacyte in Q4 2023 and held it in 4 quarters.
  • EntryPoint Capital's Humacyte position peaked at $424K in Q3 2024.
  • 162 funds tracked by Wall St. Rank held Humacyte as of Q4 2024.

Based on EntryPoint Capital's 13F filing for Q4 2024, filed 11 Feb 2025.